Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Enterprise Value (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Enterprise Value for 5 consecutive years, with -$183.8 million as the latest value for Q1 2026.

  • For Q1 2026, Enterprise Value rose 14.6% year-over-year to -$183.8 million; the TTM value through Mar 2026 reached -$183.8 million, up 14.6%, while the annual FY2025 figure was -$130.0 million, 56.69% up from the prior year.
  • Enterprise Value hit -$183.8 million in Q1 2026 for Phathom Pharmaceuticals, down from -$130.0 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$130.0 million in Q4 2025 and bottomed at -$384.3 million in Q4 2023.
  • Average Enterprise Value over 5 years is -$220.1 million, with a median of -$207.9 million recorded in 2022.
  • Year-over-year, Enterprise Value tumbled 149.92% in 2024 and then surged 59.11% in 2025.
  • Phathom Pharmaceuticals' Enterprise Value stood at -$155.9 million in 2022, then crashed by 146.49% to -$384.3 million in 2023, then rose by 21.89% to -$300.1 million in 2024, then skyrocketed by 56.69% to -$130.0 million in 2025, then tumbled by 41.39% to -$183.8 million in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$183.8 million, -$130.0 million, and -$138.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.